CAS NO: | 318-98-9 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
100mg | 电议 |
500mg | 电议 |
1 g | 电议 |
5 g | 电议 |
10 g | 电议 |
生物活性 | Propranolol hydrochloride is a nonselectiveβ-adrenergic receptor (βAR)antagonist, has high affinity for the β1AR and β2AR withKivalues of 1.8 nM and 0.8 nM, respectively[1]. Propranolol hydrochloride inhibits [3H]-DHA binding to rat brain membrane preparation with anIC50of 12 nM[2]. Propranolol hydrochloride is used for study of hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy[3]. | ||||||||||||||||||||||||
IC50& Target |
| ||||||||||||||||||||||||
体外研究 (In Vitro) | Propranolol hydrochloride (10-7M-10-3M; 24 and 48 hours) increases the total ERK1/2 levels in a dose-dependent manner, and ERK1/2 activation is observed specifically at 10-5M in HemSCs[4].Propranolol hydrochloride (10-9M-10-3M; 24 and 48 hours) significant decreases cell proliferation at 10-4M propranolol after 24 hours and 10-9M propranolol after 48 hours in HemSCs[4].Propranolol hydrochloride (50 μM-200 μM; 24 hours) increases Annexin V positivity and caspase-3 activation, rapidly induces HemSC apoptosis[4]. Western Blot Analysis[4]
Cell Viability Assay[4]
Apoptosis Analysis[4]
| ||||||||||||||||||||||||
体内研究 (In Vivo) | Propranolol hydrochloride (orally administration; 40 mg/kg; daily) significantly reduces the vessel diameter relative to the vehicle-treated implants, and increases the number of cells that expressed phosphorylated ERK1/2 within the IH Matrigel implant[4].
| ||||||||||||||||||||||||
Clinical Trial | |||||||||||||||||||||||||
分子量 | 295.80 | ||||||||||||||||||||||||
性状 | Solid | ||||||||||||||||||||||||
Formula | C16H22ClNO2 | ||||||||||||||||||||||||
CAS 号 | 318-98-9 | ||||||||||||||||||||||||
中文名称 | 盐酸普萘洛尔;盐酸普奈洛尔 | ||||||||||||||||||||||||
结构分类 |
| ||||||||||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||||||||||
储存方式 | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) | ||||||||||||||||||||||||
溶解性数据 | In Vitro: DMSO : ≥ 150 mg/mL(507.10 mM) H2O : 33.33 mg/mL(112.68 mM;Need ultrasonic) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
*以上所有助溶剂都可在本网站选购。 |